In Vivo Preclinical Data Expected to Enable Three New IND Applications to Evaluate Company’s Gamma Delta T cell Product Candidates Procel™, Isocel™, and Deltacel™ HOUSTON, June 07, 2022—-Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company … Continue reading Kiromic BioPharma (NASDAQ: KRBP) Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement